Talus Bioscience is a drug discovery and development company based in Seattle that is aiming to create new treatments for cancer, inflammation and other diseases. Recently, it received three new grants totaling $4.3 million to fuel its research. The funding comes from the National Institutes for Health and the Washington State Andy Hill CARE Fund. Talus will use the money to discover new transcription factor inhibitors for two childhood cancers and accelerate the development of transcription factor drugs.
Talus Bio’s Multiplexed Assays for the Rational Modulation Of Transcription Factors platform, or MARMOT platform, works to disrupt transcription factors to stop disease. Its new funding will be used to study the effects of drug compouds on the specific gene activities that drive diseases, as well as unexpected interactions with that could lead to potential side effects.
To date, the company has received six grant awards totaling more than $7.3 million, as well as $8.5 million in venture funding.
.jpeg)
